论文部分内容阅读
目的探讨雄激素受体(androgen receptor,AR)在人表皮生长因子受体-2(human epidermal growth factor receptor-2,Her-2)过表达型乳腺癌中的表达情况及其与临床病理间关系。方法 Her-2过表达型乳腺癌136例为观察组,同期三阴性乳腺癌45例为对照组,2组采用Envision法检测AR表达情况,分析AR不同表达情况与临床病理间的关系。结果观察组AR阳性表达率(71.3%)明显高于对照组(26.7%)(P<0.01);观察组淋巴结转移者AR阳性表达率(87.0%)高于未转移者(55.2%),Ki67(+)者AR阳性表达率(63.7%)低于Ki67(-)者(86.7%)(P<0.05),AR阳性表达率在年龄、肿瘤直径、是否绝经、TNM分期、组织学分级是否存在脉管浸润、表皮生长因子受体、CK5/6是否阳性上差异均无统计学意义(P>0.05)。结论 Her-2过表达乳腺癌中AR的表达率高,其AR的表达可能为乳腺癌的治疗提供新的靶点。
Objective To investigate the expression of androgen receptor (AR) in human epidermal growth factor receptor-2 (Her-2) overexpression breast cancer and its relationship with clinical pathology . Methods Thirty-six patients with Her-2 overexpression were selected as observation group and 45 patients with triple-negative breast cancer as control group. Envision method was used to detect the expression of AR in two groups. The relationship between the expression of AR and clinical pathology was analyzed. Results The positive expression rate of AR in observation group (71.3%) was significantly higher than that in control group (26.7%) (P <0.01). The positive expression rate of AR in observation group (87.0%) was higher than that in non-metastasis (+) Were lower than that of Ki67 (86.7%) (63.7%) (P <0.05). The positive expression rate of AR in the age, tumor diameter, menopause, TNM stage and histological grade Vascular invasion, epidermal growth factor receptor, CK5 / 6 were no significant difference was statistically significant (P> 0.05). Conclusion The expression of AR in Her-2 overexpression breast cancer is high, and the expression of AR may provide a new target for the treatment of breast cancer.